Cargando…

Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis

BACKGROUND: Recent works have suggested a possible link between interleukin (IL)-33 and B-cell biology. We aimed to study the possible association between serum IL-33 detection and response to rituximab (RTX) in rheumatoid arthritis (RA) patients in different cohorts with an accurate enzyme-linked i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sellam, Jérémie, Rivière, Elodie, Courties, Alice, Rouzaire, Paul-Olivier, Tolusso, Barbara, Vital, Edward M., Emery, Paul, Ferraciolli, Gianfranco, Soubrier, Martin, Ly, Bineta, Hendel Chavez, Houria, Taoufik, Yassine, Dougados, Maxime, Mariette, Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154136/ https://www.ncbi.nlm.nih.gov/pubmed/27964756 http://dx.doi.org/10.1186/s13075-016-1190-z

Ejemplares similares

Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
por: Sellam, Jérémie, et al.
Publicado: (2017)

Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis
por: Rivière, Elodie, et al.
Publicado: (2018)

Association between T follicular helper cells and T peripheral helper cells with B-cell biomarkers and disease activity in primary Sjögren syndrome
por: Dupré, Anastasia, et al.
Publicado: (2021)

Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
por: Gottenberg, Jacques-Eric, et al.
Publicado: (2019)

Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?
por: Ferraccioli, Gianfranco, et al.
Publicado: (2016)

Restoration of Default Blood Monocyte-Derived Macrophage Polarization With Adalimumab But Not Etanercept in Rheumatoid Arthritis
por: Paoletti, Audrey, et al.
Publicado: (2022)

CD25 Appears Non Essential for Human Peripheral T(reg) Maintenance In Vivo
por: de Goër de Herve, Marie-Ghislaine, et al.
Publicado: (2010)

Increased Production of B-Cell Activating Cytokines and Altered Peripheral B-Cell Subset Distribution during HIV-Related Classical Hodgkin Lymphoma
por: Lievin, Raphael, et al.
Publicado: (2021)

Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren’s syndrome: results of the BELISS study
por: Seror, Raphaèle, et al.
Publicado: (2015)

Refractory T-Cell Anergy and Rapidly Fatal Progressive Multifocal Leukoencephalopathy After Prolonged CTLA4 Therapy
por: Dekeyser, Manon, et al.
Publicado: (2017)

Vascular endothelial growth factor levels and rheumatic diseases of the elderly
por: Smets, Perrine, et al.
Publicado: (2016)

Increase In Il-31 Serum Levels Is Associated With Reduced Structural Damage In Early Axial Spondyloarthritis
por: Rosine, Nicolas, et al.
Publicado: (2018)

Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic
por: Dougados, Maxime
Publicado: (2021)

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2011)

Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren Syndrome
por: Pepple, Sophanit, et al.
Publicado: (2022)

Coronary heart disease is associated with a worse clinical outcome of hand osteoarthritis: a cross-sectional and longitudinal study
por: Courties, Alice, et al.
Publicado: (2017)

Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab
por: Hassan, Sabih Ul, et al.
Publicado: (2020)

A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis
por: Arnold, Jack, et al.
Publicado: (2022)

Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2017)

Time to Total Knee Arthroplasty after Intra-Articular Hyaluronic Acid or Platelet-Rich Plasma Injections: A Systematic Literature Review and Meta-Analysis
por: Berkani, Sabryne, et al.
Publicado: (2022)

Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry
por: Salmon, J H, et al.
Publicado: (2015)

Alpha-7 Nicotinic Receptor Dampens Murine Osteoblastic Response to Inflammation and Age-Related Osteoarthritis
por: Courties, Alice, et al.
Publicado: (2022)

Clearing method for 3-dimensional immunofluorescence of osteoarthritic subchondral human bone reveals peripheral cholinergic nerves
por: Courties, Alice, et al.
Publicado: (2020)

Germline Genetic Risk Variants for Progressive Multifocal Leukoencephalopathy
por: Eis, Peggy S., et al.
Publicado: (2020)

Extension Study of PF‐05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis
por: Cohen, Stanley B., et al.
Publicado: (2018)

Improved Survival of HIV-1-Infected Patients with Progressive Multifocal Leukoencephalopathy Receiving Early 5-Drug Combination Antiretroviral Therapy
por: Gasnault, Jacques, et al.
Publicado: (2011)

Resting Regulatory CD4 T Cells: A Site of HIV Persistence in Patients on Long-Term Effective Antiretroviral Therapy
por: Tran, Tu-Anh, et al.
Publicado: (2008)

Efficacy of Recombinant Human Interleukin 7 in a Patient With Severe Lymphopenia-Related Progressive Multifocal Leukoencephalopathy
por: Gasnault, Jacques, et al.
Publicado: (2014)

Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis
por: Juge, Pierre-Antoine, et al.
Publicado: (2017)

Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2023)

Pollutants: a candidate as a new risk factor for osteoarthritis—results from a systematic literature review
por: Deprouw, Camille, et al.
Publicado: (2022)

Agranulocytosis under biotherapy in rheumatoid arthritis: three cases hypothesis of parvovirus B19 involvement in agranulocytosis observed under tocilizumab and rituximab for the treatment of rheumatoid arthritis
por: Giraud, C., et al.
Publicado: (2016)

Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies
por: Petricca, Luca, et al.
Publicado: (2020)

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
por: Salliot, C, et al.
Publicado: (2009)

Rituximab Prevents Stroke Recurrences in Atypical Chronic Immune-Mediated Thrombotic Thrombocytopenic Purpura
por: Dupuy, Henry, et al.
Publicado: (2018)

Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006)

Transcutaneous vagus nerve stimulation in erosive hand osteoarthritis: protocol for the randomised, double-blind, sham-controlled ESTIVAL trial
por: Courties, Alice, et al.
Publicado: (2022)

Rituximab Efficacy during a Refractory Polyarteritis Nodosa Flare
por: Ribeiro, Emmanuel, et al.
Publicado: (2009)

Impairment of glyoxalase-1, an advanced glycation end-product detoxifying enzyme, induced by inflammation in age-related osteoarthritis
por: Trellu, Sabine, et al.
Publicado: (2019)

Effect of Transcutaneous Vagus Nerve Stimulation in Erosive Hand Osteoarthritis: Results from a Pilot Trial
por: Courties, Alice, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b1l2om5fclefamucls5n6imene